PITTSBURGH, April 7 /PRNewswire/ -- Cohera Medical Inc. today named William M. Cotter to the newly created position of vice president of manufacturing.
The addition of Cotter, who has over 29 years of manufacturing and operations experience in the medical device, diagnostics, biologics and life science industries, comes at a time when Cohera Medical is preparing to enter the clinical stage of development with its lead surgical adhesive product, TissuGlu(R).
“Bill brings to Cohera extensive industry knowledge and experience guiding product manufacturing from early-stage R&D through worldwide commercialization,” said Patrick Daly, president and CEO of Cohera Medical. “His experience will be invaluable to our company as we ramp up manufacturing activities in preparation for TissuGlu clinical trials.”
Cotter spent 10 years as the vice president of operations for Closure Medical Corporation a medical device company, acquired by Johnson & Johnson, which developed the world’s first synthetic topical skin adhesive to be approved by the U.S. Food and Drug Administration. Prior to Closure Medical, he was vice president of operations with Sanofi Diagnostics Pasteur, where he had direct responsibility for all North American manufacturing sites and chaired the worldwide manufacturing committee. Bill is listed as co-inventor on 8 U.S. patents and has a bachelor’s degree from Ohio University.
About Cohera Medical
Cohera Medical Inc. is a Pittsburgh-based company that is developing a revolutionary line of wound management products and surgical adhesives. Cohera Medical’s products are based on a unique chemical design that is purely synthetic, easy to use, biocompatible and fully resorbable. The company’s lead product in development, TissuGlu, is a sprayable bonding agent for plastic surgery procedures. TissuGlu adheres flaps of tissue after surgical procedures, eliminating the spaces where fluid accumulates and reducing wound drainage. Cohera Medical is also developing surgical adhesives targeting mesh fixation and small bone fixation, which will fill similar market needs in both orthopedics and general surgery. For more information, visit www.coheramed.com. TissuGlu and the other Cohera products have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or by any other country’s regulatory authority.
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company’s future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.
CONTACT: Robert E. Flamm, Ph.D., Robert.flamm@russopartnersllc.com, or
David Schull, Ph.D., david.schull@russopartnersllc.com, both of Russo
Partners, +1-212-845-4226, or Patrick Daly, Cohera Medical,
+1-412-231-1500, ext. 101, pdaly@coheramed.com
Web site: http://www.coheramed.com/
